{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:29:16Z","timestamp":1762352956941,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijantimicag.2020.106154","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T21:27:12Z","timestamp":1599686832000},"page":"106154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load \u226450 copies\/mL: does estimated glomerular filtration rate matter?"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-0686","authenticated-orcid":false,"given":"A.","family":"Vergori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lichtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"De Vito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. d'Arminio","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cozzi-Lepri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106154_bib0001","unstructured":"AIDSinfo. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services; 2018. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv-guidelines\/31\/adverse-effects-of-arv [accessed 11 September 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0002","unstructured":"European AIDS Clinical Society (EACS). EACS guidelines, Version n.10.0. EACS; 2019. http:\/\/www.eacsociety.org\/files\/2019_guidelines-10.0-english.pdf [accessed 11 September 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0003","unstructured":"Societ\u00e0 Italiana Malattie Infettive e Tropicali (SIMIT). Utilizzo dei farmaci antiretrovirali e gestione diagnostico-clinica delle persone con infezione da HIV-1; 8 edizione, 2017 [Use of antiretroviral drugs and diagnostic-clinical management of people with HIV-1 infection; 8 edition, 2017]. http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2696_allegato.pdf [accessed 11 September 2020]."},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0004","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0005","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/jac\/dky123","article-title":"ATLAS-M Study Group. Atazanavir\/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial","volume":"73","author":"Fabbiani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0006","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir\u2013rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"journal-title":"Clin Infect Dis","year":"2020","author":"van Wyk","key":"10.1016\/j.ijantimicag.2020.106154_bib0008"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0009","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/QAI.0000000000001344","article-title":"Brief report: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults","volume":"75","author":"Raffi","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"Orkin","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0011","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0012","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/aid.2017.0203","article-title":"Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment","volume":"34","author":"DeJesus","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(17)30031-0","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"Orkin","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0014","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/QAI.0000000000001186","article-title":"Brief report: Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study","volume":"74","author":"Post","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(18)30010-9","article-title":"Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial","volume":"5","author":"Winston","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181c990bf","article-title":"Once-daily atazanavir\/ritonavir compared with twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study","volume":"53","author":"Molina","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0018","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160761","article-title":"Long-term durability of tenofovir-based antiretroviral therapy in relation to the co-administration of other drug classes in routine clinical practice","volume":"11","author":"Costarelli","year":"2016","journal-title":"PLoS One"},{"issue":"Suppl 8","key":"10.1016\/j.ijantimicag.2020.106154_bib0020","first-page":"e25187","article-title":"on behalf of ICONA Foundation Study Group. Incidence and determinants of antiretroviral switching away from TDF-based backbone in recent years in the Icona Foundation Cohort. In: HIV Glasgow 2018, 28\u201331 October 2018, Glasgow, UK [abstract P100]","volume":"21","author":"Vergori","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 8","key":"10.1016\/j.ijantimicag.2020.106154_bib0021","first-page":"e25187","article-title":"Switch from tenofovir disoproxil fumarate (TDF)- to tenofovir alafenamide (TAF)-based regimens in clinical practice\u2014real-world data of the German PROPHET cohort study. In: HIV Glasgow 2018, 28\u201331 October 2018, Glasgow, UK [abstract P112]","volume":"21","author":"Bickel","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 8","key":"10.1016\/j.ijantimicag.2020.106154_bib0022","first-page":"e25187","article-title":"Clinical observations of antiretroviral (ART) switching in HIV-suppressed patients after availability of TAF. In: HIV Glasgow 2018, 28\u201331 October 2018, Glasgow, UK [abstract P114]","volume":"21","author":"Elion","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0023","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00002030-200003310-00005","article-title":"Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral na\u00efve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Na\u0131ve Patients","volume":"14","author":"D'Arminio","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0024","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1186\/s12879-019-4454-9","article-title":"Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort","volume":"19","author":"Surial","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0025","doi-asserted-by":"crossref","first-page":"e7363","DOI":"10.1371\/journal.pone.0073639","article-title":"Switching tenofovir\/emtricitabine plus lopinavir\/r to raltegravir plus darunavir\/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial","volume":"8","author":"Nishijima","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl 4","key":"10.1016\/j.ijantimicag.2020.106154_bib0026","first-page":"18279","article-title":"A randomized pilot study of tenofovir\/emtricitabine (TDF\/FTC)\u00a0+\u00a0boosted atazanavir (ATV\/r) vs. raltegravir (RALBID)\u00a0+\u00a0ATV\/r vs. RAL BID\u00a0+\u00a0ATV BID","volume":"15","author":"Cohen","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0027","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/QAI.0000000000000966","article-title":"NRTI sparing therapy in virologically controlled HIV-1 infected subjects: results of a controlled randomized trial (Probe)","volume":"72","author":"Maggiolo","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0028","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0029","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"LAMIDOL Study Group. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0030","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through Week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0031","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1186\/s12879-017-2755-4","article-title":"A dual regimen of ritonavir\/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data","volume":"17","author":"Capetti","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0032","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0033","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials","volume":"33","author":"Gupta","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0034","doi-asserted-by":"crossref","first-page":"e8046","DOI":"10.1097\/MD.0000000000008046","article-title":"Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report","volume":"96","author":"Novick","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0035","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients","volume":"24","author":"Mocroft","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0036","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0037","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0038","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annepidem.2016.08.016","article-title":"Does water kill? A call for less casual causal inferences","volume":"26","author":"Hern\u00e1n","year":"2016","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.ijantimicag.2020.106154_bib0039","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/hiv.12087","article-title":"INSIGHT SMART Study Group. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals","volume":"15","author":"Lucas","year":"2014","journal-title":"HIV Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:41:41Z","timestamp":1760377301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920303538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0924857920303538"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106154","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load \u226450 copies\/mL: does estimated glomerular filtration rate matter?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106154"}}